The adenomatous polyposis coli (APC) gene is mutated in familial adenomatous polyposis and in many sporadic colorectal tumors. The carboxyl-terminal S/TXV motif of the APC gene product interacts with the PDZ domain of hDLG, the human homolog of the Drosophila lethal (1) discs large-1 (dlg) tumor suppressor. In the present study, we found that overexpression of hDLG suppresses cell proliferation by blocking cell cycle progression from the G0/G1 to S phase. This inhibition of cell cycle progression was abolished when the PDZ, SH3 or guanylate kinase-like domain of hDLG was mutated. Moreover, overexpression of these mutant hDLGs partially interfered with the cell cycle blocking activity of APC. Consistent with this result, mutant APC lacking the S/TXV motif exhibited weaker cell cycle blocking activity than the intact APC. These results suggest that APC-hDLG complex formation plays an important role in transducing the APC cell cycle blocking signal.
Introduction
The APC gene was isolated from human chromosome 5q21 and found to be mutated in most cases of familial adenomatous polyposis (FAP) (Kinzler and Vogelstein, 1996) . APC has also been found to be somatically mutated in the majority of sporadic colorectal tumors. The majority of mutations occur in the 5' region of the sequence and are almost exclusively either nonsense or frame-shift mutations that result in the truncation of the APC gene product. Consistent with its role as a tumor suppressor, overexpression of APC blocks cell cycle progression from the G0/G1 to the S phase (Baeg et al., 1995) . Mutant APCs recovered from FAP and/ or sporadic colorectal tumors are less eective in inhibiting cell cycle progression than the normal APC.
The APC gene encodes a protein of 2843 amino acids that are associated with b-catenin, Axin and conductin/Axil (Rubinfeld et al., 1993; Behrens et al., 1998; Ikeda et al., 1998 Nakamura et al., 1998; Yamamoto et al., 1998) . These proteins are important components of the Wnt/ Wingless signal transduction pathway, which controls embryonic pattern formation (Nusse and Varmus, 1992; Cadigan and Nusse, 1997) . The central region of the APC protein binds to b-catenin, Axin and conductin/Axil, and downregulates the level of bcatenin, thereby repressing transcriptional activation mediated by the b-catenin-TCF/LEF family of proteins Morin et al., 1997) . Thus, in colon cancer cell lines with mutated APC, b-catenin-TCF-mediated transcription is constitutively activated. Conversely, it has recently been shown that some colorectal and other cancer cells have intact APC, but contain activating mutations in b-catenin Rubinfeld et al., 1997) .
The above ®ndings indicate that regulation of bcatenin is critical to the tumor suppressive eects of APC. In addition, however, APCs from several FAP patients were reported to contain mutations very close to the carboxyl-terminus, suggesting that the carboxylterminal region of APC is also important for its tumor suppressive eect (Miyoshi et al., 1992; Pedemonte et al., 1998) . For example, in one case of FAP a mutant APC was recovered that contains a 4 bp deletion in codon 2644 and is capable of down-regulating bcatenin-Tcf-mediated transcriptional activation (Miyoshi et al., 1992; Korinek et al., 1997; . Furthermore, one case of FAP has recently been reported to contain a single base deletion in codon 2829 (Pedemonte et al., 1998) . In this regard, it is interesting to note that the human homolog of the Drosophila discs large (dlg) tumor suppressor protein, hDLG (Lue et al., 1994) , binds to the carboxylterminus of APC (Matsumine et al., 1996) . Inactivation of Drosophila dlg is known to result in the neoplastic growth of imaginal discs epithelial cells and cause dramatic changes in the synaptic bouton structure (Woods and Bryant 1991; Woods et al., 1996) .
The hDLG protein is a member of the membraneassociated guanylate kinase (MAGUK) family of proteins whose members include DLG, PSD-95/SAP 90, PSD-93/chapsyn 110, SAP 102, ZO-1, ZO-2 and p55 (Craven and Bredt, 1998) . All of the MAGUK proteins share a common modular structure composed of several PDZ domains followed by an SH3 domain and a guanylate kinase-like domain. Despite its name, this family of proteins may not possess functional guanylate kinase activity, since key amino acid residues required for ATP binding are not conserved. Instead, this guanylate kinase-like domain appears to function as site of interaction with other proteins such as DLGAP-1-4 (DAP-1a and -2/SAPAP-1 and -2, DAP1b/GKAP, and SAPAP-3 and -4) Satoh et al., 1997; Takeuchi et al., 1997) .
The PDZ domain is made up of *90 amino acids and contains a conserved GLGF motif. This domain mediates protein ± protein interactions, binding to the carboxyl-terminal S/TXV motif (S/T, serine or threonine; X, any amino acid; V, valine) of target proteins. The PDZ domain of hDLG binds to the carboxyl-terminal S/TXV motif of APC (Matsumine et al., 1996) . Furthermore, the PDZ domains of some MAGUKs interact with membrane proteins such as the NMDA-type glutamate receptors and shaker-type K + channels, thereby inducing the clustering of these ion channels (Kornau et al., 1995; Kim et al., 1995) .
In addition to APC, several proteins implicated in tumorigenesis have also been reported to interact with the PDZ domain of hDLG. For example, the high-risk human papilloma virus E6 oncoprotein, adenovirus E4 oncoprotein and human T cell leukemia virus type 1 Tax protein also bind to the second PDZ domain of hDLG (Kiyono et al., 1997; Lee et al., 1997) . These ®ndings further suggest that hDLG may play an important role in the negative regulation of cell proliferation.
In the present study, we studied the signi®cance of the interaction between APC and hDLG for cell proliferation. We found that overexpression of hDLG blocks cell cycle progression from the G0/G1 to S phase. Overexpression of mutant hDLGs interfered with the cell cycle blocking activity of APC. Furthermore, mutant APC lacking the interaction sites fail to eectively block cell cycle progression, suggesting that APC-hDLG complex formation is necessary for cell cycle inhibition.
Results
To understand the signi®cance of the interaction between APC and hDLG, we ®rst examined whether hDLG itself has a potential to negatively regulate the proliferation of mouse ®broblast NIH3T3 cells. Mouse DLG is expressed in NIH3T3 cells while mouse APC is barely detectable. The hDLG cDNA and a series of mutants diagrammed in Figure 1 were each inserted downstream of the SRa promoter in an expression vector containing the geneticin resistant gene. PDZ domain mutants were generated by replacing the conserved Gly-Leu-Gly-Phe motifs in each of the three PDZ repeats with Gly-Arg-Arg-Phe. We con®rmed that this mutant is not able to interact with APC (our unpublished observations). A mutant possessing an inactive SH3 domain (hDLG-SH3WK), was generated by replacing Trp-623 with Lys, based on the observation that the corresponding Trp in the SH3 domain of v-Src SH3 domain or p47 phox SH3 is essential for its function (Liu et al., 1993; de Mendez et al., 1997) . hDLG ± DSH3 is a mutant in which Val-640 in the SH3 domain has been replaced with a stop codon. We also generated a mutant identical to the Drosophila mutant dlg v59 previously reported (Woods and Bryant, 1991) by replacing Met-791 in the guanylate kinase-like (GUK) domain with a stop codon. hDLG ± GK2 is a mutant in which Arg-773, a residue in the GUK domain important for GMPbinding (Kistner et al., 1995) , is replaced with Glu. Immunoblotting experiments showed that each of these expression vectors produced proteins of expected sizes when transfected into COS-7 cells (data not shown). NIH3T3 cells were transfected with each expression vector and transfectants were selected by culturing in the presence of geneticin. After two weeks, the numbers of geneticin-resistant colonies were counted ( Figure 2 ). Cells transfected with the wild-type hDLG expression plasmid formed ®vefold fewer geneticinresistant colonies than those transfected with the vector alone. In contrast, none of the mutant hDLGs described above had any signi®cant eect on colony formation. The small number of geneticin resistant colonies that appeared following wild-type hDLG transfection did not express detectable level of hDLG. These colonies apparently lost the expression of hDLG while retaining geneticin resistance. Colonies that appeared after transfection of various hDLG mutants expressed appropriate proteins. These results suggest that hDLG possesses the ability to inhibit cell Figure 1 Schematic representation of the structure of the wild type and mutant hDLG proteins. GRRF, a mutant in which the conserved Gly-Leu-Gly-Phe motifs in each of the three PDZ repeats are replaced with Gly-Arg-Arg-Phe; DSH3, a mutant in which Val-640 in the SH3 domain is replaced with a stop codon; SH3WK, a point mutant in which Trp-623 in the SH3 domain is replaced with Lys; GK1, a mutant in which Met-791 in the GUK domain is replaced with a stop codon; GK2, a mutant in which Arg-773 in the GUK domain is replaced with Glu Negative regulation of G1/S transition by APC-hDLG complex T Ishidate et al proliferation and that intact PDZ, SH3 and GUK domains are required for this activity.
To further characterize the growth inhibitory activity of hDLG, we microinjected the hDLG expression plasmid into serum-starved, quiescent NIH3T3 cells and examined its eect on seruminduced cell cycle progression. Progression from the G0/G1 to S phase was determined by examining the ratio of microinjected cells that incorporated bromodeoxyuridine (BrdU). We found that cells microinjected with the wild-type hDLG expression plasmid exhibited signi®cantly lower BrdU incorporation than those injected with the control vector (Figure 3) . Consistent with the results of the colony formation assay, microinjection of the mutant hDLGs described above had no eect on the G0/G1-S transition. These results suggest that hDLG suppresses cell growth, at least in part, by blocking cell cycle progression from the G0/G1 to S phase.
We previously demonstrated that overexpression of APC blocks G0/G1 to S phase cell cycle progression (Baeg et al., 1995) . We therefore examined whether formation of the APC-hDLG complex is required for the cell cycle blocking activity of APC. As reported previously, cell cycle progression was signi®cantly inhibited when an APC expression plasmid was microinjected into NIH3T3 cells (Figure 4) . Interestingly, however, the cell cycle blocking activity of APC was partially alleviated when APC was microinjected along with any of the mutant hDLGs: hDLG ± a Negative regulation of G1/S transition by APC-hDLG complex T Ishidate et al GRRF, ± SH3WK, ± DSH3, ± GK1 or ± GK2. These mutant hDLGs may act as dominant-negative mutants that inhibit the formation of the intact APC ± hDLG complex. If so, this ®nding suggests that APC may need to form a complex with intact hDLG to eectively block the cell cycle. Consistent with this notion, the mutant APC that lacks the carboxyterminal Thr-Ser-Val was less eective in inhibiting the G0/G1-S transition than intact APC. APC is known to negatively regulate the Wnt signaling transduction pathway by inducing the degradation of b-catenin, and this activity is believed to be essential for its tumor suppressor function (Rubinfeld et al., 1993; Su et al., 1993; Munemitsu et al., 1995) . We therefore examined whether hDLG is involved in this process. When we microinjected the intact hDLG or any of the mutant hDLGs into the human colon cancer cell line SW480, we could not detect the degradation of b-catenin by immunostaining ( Figure 5 ). In contrast, microinjection of APC resulted in a drastic reduction in the levels of b-catenin, as reported previously (Munemitsu et al., 1995) . This eect was not attenuated by co-injection of any of the mutant hDLGs. These results suggest that formation of the APC ± hDLG complex is not required for the degradation of b-catenin, at least when APC is overexpressed in SW480 cells.
To further study the relationship between the APC ± hDLG mediated cell cycle block and degradation of bcatenin, we examined the eect of APC on the growth of two cell lines: one, HCT-116, contains intact APC and mutated b-catenin, while the other, SW480, contains mutated APC and intact b-catenin . Colony formation assays showed that overexpression of APC blocks the growth of these cell lines to a similar extent, regardless of the state of b-catenin (Figure 6 ). This result suggests that APC exerts its eect, at least in part, by a mechanism that is independent of b-catenin degradation.
Discussion
The lethal (1) discs large-1 (dlg) mutant of Drosophila was originally identi®ed in a genetic screen for recessive lethal mutations. This mutation causes the deregulated and tumorous proliferation of imaginal disc epithelial cells (Stewart et al., 1972) . The product of the dlg gene has been shown to localize at the septate junctions and to be required for maintaining proper junction structure, cell polarity and control of cell proliferation (Woods and Bryant, 1991; Woods et al., 1996) . We therefore hypothesized that hDLG, the human homolog of dlg, might also be involved in the negative regulation of cell growth. The results of a colony formation assay showed that hDLG inhibits the b Figure 4 The mutant hDLGs blocks APC-induced cell cycle block in a dominant negative manner. Serum-starved NIH3T3 cells were microinjected with the mixture of expression plasmids, and monitored for BrdU incorporation. (a) Cells were injected with wild-type APC (a ± c), APC and GRRF mutant (d ± f), APC and DSH3 mutant (g ± i), APC and GK1 mutant (j ± l), APC and GK2 mutant (m ± o), or APCDTSV, a mutant APC in which the carboxyl-terminal three amino acid residues, Thr-Ser-Val, are deleted, and stained with anti-GFP antibody (left row), BrdU-antibody (middle row), or DAPI (right row). Arrowheads point to representative cells that were microinjected. Our experiments with mutant hDLGs showed that the intact PDZ, SH3 and GUK domains are required for the cell cycle blocking activity of hDLG. This ®nding is consistent with studies on Drosophila dlg showing that the GUK domain and the amino-terminal region containing the PDZ domains are required for the tumor suppressor function of dlg (Woods and Bryant, 1991; Woods et al., 1996) . Furthermore, in studies using transgenic¯ies, it was shown that the second and third PDZ domains, the SH3 domain, and a region between the SH3 and GUK domains called the HOOK domain are all required for rescue of the overgrowth phenotype of imaginal disc epithelium in dlg-null larvae (Hough et al., 1997) . Since the PDZ, SH3 and GUK domains are believed to constitute protein-interaction interfaces, structural alterations in these domains may abrogate the ability of hDLG to interact with key regulatory or eector molecules. In addition, the HOOK domain and the second PDZ domain have been shown to be important for the correct localization of some proteins at the membrane and at the septate junction, respectively (Hough et al., 1997) . It is also well known that MAGUKs are involved in the clustering of membrane proteins (Kornau et al., 1995; Kim et al., 1995) . However, since only the amino-terminus and the ®rst and second PDZ domains are required for this function , the growth suppressing ability of hDLG can not solely be attributed to its cluster-inducing activity.
Co-microinjection of plasmids encoding hDLG mutants antagonized the ability of APC expression to block the cell cycle. It is likely that this interference is caused by a dominant-negative mechanism: overexpressed mutant hDLGs (hDLG ± SH3WK, ± DSH3, ± GK1 and ± GK2) bind to APC and form nonfunctional complexes, i.e. unable to interact with critical molecules required for transmitting the cell cycle blocking signal. Similarly, hDLG ± GRRF, which is not able to bind APC, may compete with the APCassociated wild-type hDLG for binding to critical molecules. Finally, APC ± DTSV, a mutant APC lacking the carboxy-terminal hDLG-binding site, exhibited reduced cell cycle blocking activity compared to wild-type APC. These ®ndings suggest that a functional APC ± hDLG complex is required to eciently transduce the cell cycle blocking signal. In this regard, it is interesting to note that a few FAP patients have been reported to have mutations very near the carboxyl-terminal region of APC (Miyoshi et al., 1992; Pedemonte et al., 1998) . One of these mutant APCs, which contains a 4 bp deletion in codon 2644, was reported to retain full b-catenin degradation activity Morin et al., 1997) . Furthermore, one case of FAP has been reported to contain a single base deletion at codon 2829 (Pedemonte et al., 1998) . This deletion causes frameshifting and predicts the generation of a mutant APC, in which a novel 10mer peptide substitutes the ®nal 14 amino acids of the normal APC. Thus, our results provide one possible mechanism for the pathogenesis observed in cases of FAP that do not involve the b-catenin pathway. We further note that several human viral oncoproteins, including the papilloma virus E6 protein, the adenovirus E4 protein, and HTLV Tax, bind to the same PDZ domain of hDLG as APC. We speculate that these oncoproteins may compete with APC for binding to hDLG and prevent the formation of APC ± hDLG complexes, thereby suppressing the cell cycle inhibition function of these complexes. It should be noted, however, that the alleviation of APC-induced cell cycle block by overexpression of mutant hDLGs was only partial. Similarly, cell cycle inhibition by the APC ± DTSV mutant was also partial. These results imply that APC exerts its cell cycle suppressing eect not only through its interaction with hDLG, but also through pathways independent of hDLG. Recently, b-catenin has been shown to activate transcription of the cyclin D1 gene through TCF/LEFbinding sites present in the promoter (He et al., 1998) . Moreover, overexpression of a dominant-negative TCF mutant has been shown to cause G1 arrest of the colon cancer cell line HCT116 in a manner rescueable by overexpression of cyclin D1 (He et al., 1998) . These ®ndings suggest that APC blocks cell cycle progression by down-regulating cyclin D1 expression through the negative regulation of b-catenin. On the other hand, our colony formation assay clearly showed that overexpression of APC suppresses proliferation of HCT116, even though this cell line contains a mutated b-catenin that is resistant to APC-mediated degradation. Thus, APC seems to control cell proliferation through several signaling pathways, including the bcatenin-and hDLG-dependent pathways. In addition, our microinjection experiments showed that hDLG may not be involved in the degradation of b-catenin, consistent with the idea that the b-catenin-and hDLGdependent pathways are independent of each other.
In conclusion, our results in cultured cells show that APC ± hDLG complex formation is important in inducing a cell cycle suppression signal, and that this signal is independent of the b-catenin-mediated signal. Identi®cation of additional upstream and downstream components of this pathway will clarify the molecular mechanism underlying cell growth suppression mediated by the APC ± hDLG complex.
Materials and methods

Cell culture
NIH3T3 cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% calf serum. For serum starvation, NIH3T3 cells were cultured in DMEM containing 0.4% calf serum for 24 h. SW480 cells were cultured in L15 medium supplemented with 10% fetal calf serum. HCT116 cells were cultured in McCoy's 5A medium supplemented with 10% fetal calf serum.
Plasmid construction
Mutant hDLGs were generated by site-directed mutagenesis using the following primers; 5'-GGAAATTCAGGGCGT-CGTTTCAGCATTGCA-3', 5'-GGTCCTAAAGGTCGTC-GGTTTAGCATTGCT-3', and 5'-GGCTCAACGGGCCG-TCGTTTCAACATTGTA-3' for GRRF mutant; 5'-TCTGA-TGATGAAAAGTGGCAAGCCAGGCAG-3' for SH3WK mutant; 5'-AGCGATGAGGTCGGATAAATTCCCAGTA-AACGC-3' for DSH3 mutant; 5'-TCAAGAGAGCAGTAG-GAAAAAGATATCCAGGA-3' for GK1 mutant; and 5'-CAACTAGACCAAAAGAGGATTATGAGGTAG-3' for GK2 mutant. To generate the APC ± DTSV mutant, the carboxy-terminal region of APC was PCR ampli®ed and Thr-2841 changed to a stop codon using the following primers: 5'-GCGGATCCAGTTCACCTAGTGGGACTGTT-3' and 5'-GCGGATCCTTAAACAGATTACACAAGGTA AGA-3'. The PCR product was cloned into the BamHI site of the pBluscript vector and its sequence con®rmed. It was then subcloned into pMKIT-APC (Baeg et al., 1995) using the DraIII site in the APC cDNA and the BamHI site in the multicloning site.
Microinjection and cell staining NIH3T3 cells were seeded onto coverslips (1610 4 cells/cm 2 ) and cultured in DMEM containing 0.4% calf serum 24 h before microinjection. The normal or mutated hDLG expression plasmid or the APC expression plasmid, along with the GFP expression plasmid, were microinjected into the nuclei of cells using a Microinjector 5880 (Eppendorf). The concentrations of the injected plasmids were 200 mg/ml unless otherwise stated. After microinjection, the cells were further cultured in DMEM containing 0.4% calf serum for 12 h. The medium was then changed to fresh DMEM containing 10% calf serum and 50 mM bromodeoxyuridine. After culturing for 16 ± 18 h, the cells were ®xed in 3.7% formaldehyde in PBS for 30 min, treated with 100% methanol for 10 min and then treated with IN HCl for 10 min. The microinjected cells were identi®ed by staining with anti-GFP polyclonal antibody (1 : 500 dilution) (Clontech) and¯uorescein-5-isothiocyanate (FITC)-conjugated goat anti-rabbit IgG (Cappel). BrdU was detected with an anti-bromodeoxyuridine (BrdU) monoclonal antibody BU-4 (1 : 100 dilution) (Takara) followed by tetramethylrhodamine -5 -(and -6) -isothiocyanate (TRITC) -conjugated goat anti-mouse IgG (Cappel).
Colony forming assay
Mouse NIH3T3 cells (2610 5 cells/ 6 cm dish) were transfected with 50 mg of various expression plasmids using the Lipofectamine reagent (Gibco ± BRL) following the manufacturer's instructions. After incubation for 24 h, cells were trypsinized and diluted 1 : 30, and cultured in DMEM containing 10% calf serum and geneticin (500 mg/ml) for 2 weeks. The plates were ®xed with 100% methanol and stained with Giemsa reagent (Gibco ± BRL).
